Erratum: Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin (International Journal of Hematology DOI: 10.1007/s12185-012-1209-4);Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin

International Journal of Hematology

Volumn 96, Issue 6, 2012, Pages 773-780

  Hatanaka, Kazuo ^a,b   Fuji, Shigeo ^c   Ikegame, Kazuhiro ^d,e   Kato, Ruri ^d,e   Wake, Atsushi ^f   Hidaka, Michihiro ^g   Ito, Toshiro ^h   Inoue, Masami ⁱ   Nagatoshi, Yoshihisa ^j,k   Takami, Akiyoshi ^l   Uike, Naokuni ^j   Sakamaki, Hisashi ^m   Yabe, Hiromasa ⁿ   Morishima, Yasuo ^o   Suzuki, Ritsuro ^p   Atsuta, Yoshiko ^p   Fukuda, Takahiro ^c  

^a WAKAYAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b Rinku General Medical Center   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e OSAKA UNIVERSITY HOSPITAL   (Japan)

^f TORANOMON HOSPITAL   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^h SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^j NATIONAL KYUSHU CANCER CENTER   (Japan)

^k FUKUOKA NATIONAL HOSPITAL   (Japan)

^l KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^m TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

ⁿ TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o AICHI CANCER CENTER HOSPITAL   (Japan)

^p NAGOYA UNIVERSITY   (Japan)

more..

Author keywords

ATG; GVHD; Unrelated bone marrow transplant

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; HLA ANTIGEN; MELPHALAN; METHOTREXATE; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RADIOTHERAPY; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DRUG MEGADOSE; ENGRAFTMENT; FEMALE; FOLLOW UP; HLA TYPING; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; JAPANESE; LOW DRUG DOSE; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PROBABILITY; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SCHOOL CHILD; WHOLE BODY RADIATION; ACUTE DISEASE; ALLOTRANSPLANTATION; CHRONIC DISEASE; DOSE RESPONSE; EVALUATION; GRAFT VERSUS HOST REACTION; HEALTH SURVEY; HEMATOLOGIC DISEASE; IMMUNOLOGY; INCIDENCE; JAPAN; KAPLAN MEIER METHOD; LIVING DONOR; MIDDLE AGED; QUESTIONNAIRE; T LYMPHOCYTE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; HEALTH SURVEYS; HEMATOLOGIC DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFANT; JAPAN; KAPLAN-MEIER ESTIMATE; LIVING DONORS; MALE; MIDDLE AGED; QUESTIONNAIRES; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875253604     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1238-z     Document Type: Erratum

References (20)

1. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091-101.
2. Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011;29:805-13.
3. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855-64.
4. Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117:6375-82.
5. Kumar A, Mhaskar AR, Reljic T, Mhaskar RS, Kharfan-Dabaja MA, Anasetti C, et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. 2012;26:582-8.
6. Oh H, Loberiza FR Jr, Zhang MJ, Ringdén O, Akiyama H, Asai T, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005;105:1408-16. (Pubitemid 40223655)
7. Hahn T, McCarthy PL Jr, Zhang MJ, Wang D, Arora M, Frangoul H, et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol. 2008;26:5728-34.
8. Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2009;15:704-17.
9. Remberger M, Svahn BM, Mattsson J, Ringdén O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation. 2004;78:122-7.
10. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387-94. (Pubitemid 46965279)
11. Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86:269-74. (Pubitemid 350085818)
12. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
13. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-8.
14. Kanda Y. Free statistical software: EZR (Easy R) on R commander. http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html. Accessed 1 Apr 2012.
15. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628-33.
16. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367-9.
17. Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99:4200-6. (Pubitemid 35332066)
18. Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C, et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse: a report from the Japan Marrow Donor Program. Br J Haematol. 2007;137:142-51. (Pubitemid 46474715)
19. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12:560-5. (Pubitemid 43956361)
20. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117:6963-70.